tldrdailynews.com logo

ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA

1 min read
Source: Nasdaq
ImmunityBio stock climbs as FDA maps resubmission route for ANKTIVA
Photo: Nasdaq
TL;DR

ImmunityBio (IBRX) shares rose about 26% after the FDA outlined a potential resubmission path for ANKTIVA in BCG-unresponsive papillary non-muscle invasive bladder cancer, saying additional information is needed to support a supplemental Biologics License Application but no new clinical trials are required, a development investors view as de-risking the regulatory process and potentially enabling a broader label. Trading volume surged on Nasdaq amid the regulatory update and ongoing volatility around ANKTIVA’s commercialization prospects.

Topics:businessmarkets#anktiva#bladder-cancer#fda#ibrx#immunitybio#markets
Share this article
  1. ImmunityBio Stock Surges 26% After FDA Outlines Resubmission Path For ANKTIVA  Nasdaq
  2. ImmunityBio (IBRX) Soars 137% on Expansion Plan, Clinical Results  Yahoo Finance
  3. ImmunityBio tries again in papillary bladder cancer | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline
  4. ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA  Business Wire
  5. ImmunityBio gets FDA views on Anktiva label expansion (IBRX)  Seeking Alpha

Want the full story? Read the original reporting

Read on Nasdaq